Can the Reduction of Cytokines Stop the Progression of Sepsis?

Basit Öğe Kaydı
dc.authorid0000-0003-2119-3801
dc.authorid0000-0003-3343-8650
dc.authorid0000-0001-9750-1028
dc.contributor.authorKoc, Suna
dc.contributor.authorCelebi, Serdar
dc.contributor.authorHanikoglu, Ferhat
dc.contributor.authorPolat, Yalcin
dc.contributor.authorUysal, Betul Borku
dc.contributor.authorDokur, Mehmet
dc.contributor.authorOzer, Turkan
dc.date.accessioned2026-01-24T12:26:52Z
dc.date.available2026-01-24T12:26:52Z
dc.date.issued2022
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractObjective In this study, we aimed to analyze the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock. Methods The levels of procalcitonin (PCT) and C-reactive protein (CRP), determined to be indicators of infection/sepsis, and the levels of interleukins (IL-6, IL-8, and IL-10) and tumor necrosis factor alpha (TNF alpha), deemed as indicators of the cytokine storm, were compared among 32 patients before and after the hemadsorption procedure. Results The hemadsorption significantly reduced the levels of IL-6, IL-8, IL-10, TNF alpha, PCT, CRP, Acute Physiology and Chronic Health Evaluation (APACHE) scores, mortality rate, and Sequential Organ Failure Assessment (SOFA) scores (p<0.05). APACHE scores and the mean predicted mortality rate (PMR) of the non-survivors measured before the procedure was significantly higher than those of survivors (p=0.002 for both). IL-10, APACHE scores, and the mortality rates determined before the hemadsorption procedure were deemed significant parameters to predict the mortality among all ICU patients (p 0.05). IL-10 levels <= 125.3 ng/L, APACHE score 30, and PMR >70.33 were significantly associated with the mortality rates of all patients, indicating that these three parameters determined before the hemadsorption may be good predictors of mortality among ICU patients with sepsis. Conclusion The progression of sepsis in ICU patients may be prevented with cytokine hemadsorption applied as an immunomodulator therapy.
dc.identifier.doi10.7759/cureus.22325
dc.identifier.issn2168-8184
dc.identifier.issue2
dc.identifier.pmid35317038
dc.identifier.urihttps://doi.org/10.7759/cureus.22325
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4960
dc.identifier.volume14
dc.identifier.wosWOS:000757946600008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringernature
dc.relation.ispartofCureus Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectintensive care
dc.subjectinterleukin
dc.subjectmortality
dc.subjectcytokine hemadsorption
dc.subjectsepsis
dc.titleCan the Reduction of Cytokines Stop the Progression of Sepsis?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu